Topiramate (All indications)

Neural Tube Defects

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8575
R28529
Tomson (Topiramate), 2018 Neural tube defects at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 5.53 [0.22;136.28] C 0/152   1/2,514 1 152
ref
S10297
R37720
Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013 Neural Tube Malformations at least 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 7.23 [0.14;369.08] C
excluded (control group)
0/44   0/315 0 44
ref
S10298
R37730
Vajda (Topiramate) (Controls unexposed, sick), 2013 Neural Tube Malformations at least 1st trimester prospective cohort unexposed, sick Adjustment: No 3.37 [0.07;172.23] C 0/44   0/147 0 44
ref
S10221
R37444
Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012 Neural tube defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 0.87 [0.04;18.16] C 0/359   2/1,562 2 359
ref
S8569
R28508
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Neural tube defect 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 7.82 [0.31;196.48] C 0/28   1/647 1 28
ref
Total 4 studies 3.21 [0.62;16.76] 4 583
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Topiramate), 2018Tomson, 2018 1 5.53[0.22; 136.28]115227%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Vajda (Topiramate) (Controls unexposed, sick), 2013Vajda, 2013 2 3.37[0.07; 172.23]04418%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012Hernández-Díaz, 2012 3 0.87[0.04; 18.16]235930%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 4 7.82[0.31; 196.48]12826%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 3.21[0.62; 16.76]45830.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate; 2: Topiramate) (Controls unexposed, sick; 3: Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications; 4: Topiramate) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.21[0.62; 16.76]45830%NATomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 4 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 3.37[0.07; 172.23]-44 -NAVajda (Topiramate) (Controls unexposed, sick), 2013 1 exposed to other treatment, sickexposed to other treatment, sick 3.18[0.52; 19.63]45390%NATomson (Topiramate), 2018 Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 3 Tags Adjustment   - No  - No 3.21[0.62; 16.76]45830%NATomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 4 All studiesAll studies 3.21[0.62; 16.76]45830%NATomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 40.220.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.75.92.4090.000Tomson (Topiramate), 2018Vajda (Topiramate) (Controls unexposed, sick), 2013Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 10297

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 3.37[0.07; 172.23]-44 -NAVajda (Topiramate) (Controls unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.68[0.70; 19.18]45830%NATomson (Topiramate), 2018 Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013 Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 40.510.01.0